Similarly, pharmacological inhibition of inflammatory cytokines elevated in individuals with CHIP, such as IL-1 beta (anakinra) and IL-18 (tadekinig alfa), holds promise for attenuating AF onset and progression. This evidence concerns the gene STUB1 and atrial fibrillation.